Partner of Choice for Global Brands

About us
Inner Banner

Milestones

SKPL, since its inception has had a remarkable journey by re-aligning its growth strategies to the changing market demands. Its many achievements include maintaining leadership position in all markets they chose to serve and its ability to deliver products that consistently meet the stringent global regulatory standards.

calendar
  • Integrated all the units under Sri Krishna group under one umbrella - Sri Krishna Pharmaceuticals Limited
  • Uppal Facility (Unit 1) receives the following certificates:
    • TGA Surveillance Certification for Acetaminophen (Paracetamol)
    • USFDA Surveillance Inspection for Acetaminophen (Paracetamol)
    • WHO GMP Surveillance inspection for Acetaminophen (Paracetamol), Domperidone & Domperidone Maleate
  • Nacharam Facility (Unit II) renews the following GMP Compliance certificates:
    • German Regulatory (Baden- Wurttemberg Drug Monitoring Control Centre) - EU GMP Compliance for Acetaminophen (Paracetamol)& Perindopril Granules
    • ANVISA (Brazilian Regulatory Authority) - GMP Compliance for Levetiracetam Granules
    • COFEPRIS (Mexican Regulatory Authority) - GMP Compliance for Acetaminophen 90% DC Granules, Acetaminophen 93% DC Granules, Acetaminophen 95% DC Granules, Ibuprofen 90% DC Granules, Metformin 90% DC Granules, Levetiracetam Granule
    • Gains AIFA (Agenzia Italian Farmaco Authority) approval for all solid dosage formats
  • Shamshabad facility (Unit III) receives the following certificates:
    • Surveillance inspection and certification by USFDA for Folic Acid manufacturing
2010-2014
calendar
  • Received TGA, AFSSAPS approval for Acetaminophen (Paracetamol)
  • Received AIFA, AFSSAPS approval for Domperidone and Domperidone Malate
  • USFDA Inspection for Acetaminophen (Paracetamol)
  • WHO GMP for Acetaminophen (Paracetamol), Domperidone & Domperidone Maleate
  • DC grades roll out at our Nacharam facility (Unit II)
  • As forward integration strategy, started formulation manufacturing facility with Acetaminophen (Paracetamol) (and other products) at our facility at Nacharam( Unit II)
  • Nacharam Facility (Unit II) receives AIFA (Agenzia Italian Farmaco Authority) IT/E/GMP/4/2009 GMP Compliance certification
  • Nacharam Facility ( Unit II) achieves TGA (Therapeutic Goods Administration) - GMP Compliance
  • Nacharam Facility ( Unit II) receives the ISO9001:2008 (AQA) IN 013630 QMS Compliance
  • USFDA(Food and Drugs Administration) for GMP Compliance for Acetaminophen Granules DC 90%
  • Sri Krishna Drugs acquires Arandy Labs, in Bollaram (Unit IV), India a niche API manufacturing facility, manufacturer of anti-diabetic range of products
  • Established another manufacturing facility Solapur (Unit V), Maharashtra to manufacture custom synthesized intermediates
2000-2009
calendar
  • Upgraded our facility at Uppal (Unit-I) with a focus on compliance with GMP practices on the following:
    • Auto Transferring of process materials from one stage to the next
    • Up gradation of Classified Clean rooms with environmental controls to protect the product quality, safety and efficacy
    • Decentralized activities for better and efficient controls for all the manufacturing activities
    • Efficient material handling systems for huge volumes
1990-1999
calendar
  • Set up 3rd facility at Shamshabad ( Unit III) as Sri Krishna Drugs incorporating the learnings gained from our facility at Uppal (Unit I)
  • Sri Krishna Drugs becomes the 1st private sector company in India to manufacture folic acid
1980-1989
calendar
  • Sri Krishna Pharmaceuticals was established in Uppal (Unit I), Hyderabad, India by Dr. V V Subba Reddy, Chairman, on his return from USA after a Post. Doc Stint at NIH, Maryland
  • Production goes live for Acetaminophen (Paracetamol) at the Uppal facility
1974- 1979